The race is on: bispecifics vs CAR T cells in B-cell lymphoma.
作者信息
Gurumurthi Ashwath, Westin Jason, Subklewe Marion
机构信息
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
Gene Center and Department of Biochemistry, Ludwig-Maximilians-Universität München, Munich, Germany.
出版信息
Blood Adv. 2023 Oct 10;7(19):5713-5716. doi: 10.1182/bloodadvances.2022009066.
Abstract
摘要
相似文献
1
The race is on: bispecifics vs CAR T cells in B-cell lymphoma.竞赛正在进行：双特异性抗体与CAR-T细胞治疗B细胞淋巴瘤的较量。
Blood Adv. 2023 Oct 10;7(19):5713-5716. doi: 10.1182/bloodadvances.2022009066.
2
Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.CD22/CD19 嵌合抗原受体 T 细胞疗法治疗累及胃肠道的复发/难治性侵袭性 B 细胞淋巴瘤患者的疗效和毒性。
Cytotherapy. 2020 Mar;22(3):166-171. doi: 10.1016/j.jcyt.2020.01.008. Epub 2020 Feb 13.
3
T cells redirected against Igβ for the immunotherapy of B cell lymphoma.针对 Igβ 的 T 细胞重定向用于 B 细胞淋巴瘤的免疫治疗。
Leukemia. 2020 Mar;34(3):821-830. doi: 10.1038/s41375-019-0607-5. Epub 2019 Oct 17.
4
CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma.嵌合抗原受体 T 细胞增强对 B 细胞成熟抗原的敏感性，用于靶向治疗 B 细胞非霍奇金淋巴瘤和多发性骨髓瘤。
Mol Ther. 2018 Aug 1;26(8):1906-1920. doi: 10.1016/j.ymthe.2018.06.012. Epub 2018 Jun 18.
5
A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells.用于CD19嵌合抗原受体T细胞临床前评估的同基因小鼠B细胞淋巴瘤模型
J Vis Exp. 2018 Oct 16(140):58492. doi: 10.3791/58492.
6
Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma.嵌合受体抗 CD19 或抗 CD38 联合利妥昔单抗的 T 细胞免疫治疗对 B 细胞非霍奇金淋巴瘤的协同和持续作用。
Br J Haematol. 2010 Oct;151(1):37-46. doi: 10.1111/j.1365-2141.2010.08297.x. Epub 2010 Jul 30.
7
Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE).三代抗 CD19 嵌合抗原受体 T 细胞融合 TLR2 结构域治疗复发或难治性 B 细胞淋巴瘤：一项 I 期临床试验方案（ENABLE）。
BMJ Open. 2020 Feb 9;10(2):e034629. doi: 10.1136/bmjopen-2019-034629.
8
Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma.针对B细胞非霍奇金淋巴瘤中CD38的嵌合受体激活T细胞介导的免疫疗法。
J Immunother. 2009 Sep;32(7):737-43. doi: 10.1097/CJI.0b013e3181adaff1.
9
Activity of Anti-CD19 Chimeric Antigen Receptor T Cells Against B Cell Lymphoma Is Enhanced by Antibody-Targeted Interferon-Alpha.抗 CD19 嵌合抗原受体 T 细胞对 B 细胞淋巴瘤的活性通过抗体靶向干扰素-α增强。
J Interferon Cytokine Res. 2018 Jun;38(6):239-254. doi: 10.1089/jir.2018.0030.
10
Bryostatin Activates CAR T-Cell Antigen-Non-Specific Killing (CTAK), and CAR-T NK-Like Killing for Pre-B ALL, While Blocking Cytolysis of a Burkitt Lymphoma Cell Line.苔藓抑素激活 CAR T 细胞抗原非特异性杀伤（CTAK）和 CAR-TNK 样杀伤用于前体 B 细胞急性淋巴细胞白血病，同时阻止 Burkitt 淋巴瘤细胞系的细胞溶解。
Front Immunol. 2022 Feb 9;13:825364. doi: 10.3389/fimmu.2022.825364. eCollection 2022.
引用本文的文献
1
Bispecific Antibodies-A New Hope for Patients with Diffuse Large B-Cell Lymphoma.双特异性抗体——弥漫性大B细胞淋巴瘤患者的新希望。
J Clin Med. 2025 Aug 6;14(15):5534. doi: 10.3390/jcm14155534.
2
Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed/refractory B non-Hodgkin lymphoma: Final analysis of a phase II trial from the LYSA group.阿替利珠单抗、奥滨尤妥珠单抗和维奈克拉治疗复发/难治性B细胞非霍奇金淋巴瘤患者：来自LYSA组的一项II期试验的最终分析
Br J Haematol. 2025 Jul;207(1):110-122. doi: 10.1111/bjh.20109. Epub 2025 Apr 26.
3
STING activation improves T-cell-engaging immunotherapy for acute myeloid leukemia.STING激活可改善急性髓系白血病的T细胞接合免疫疗法。
Blood. 2025 May 8;145(19):2149-2160. doi: 10.1182/blood.2024026934.
4
Economic evaluation of critically ill adult CAR-T cell recipients-analysis from a healthcare payer perspective.危重症成年CAR-T细胞治疗受者的经济学评估——从医疗保健支付方角度进行的分析
Med Klin Intensivmed Notfmed. 2024 Dec 30. doi: 10.1007/s00063-024-01230-z.
5
Celebrating a year of immunotherapy/cell and gene therapy in Blood Advances.庆祝《血液进展》中免疫疗法/细胞与基因疗法的一年。
Blood Adv. 2024 Dec 24;8(24):6334-6336. doi: 10.1182/bloodadvances.2024015305.
6
Recommendations for the effective use of T-cell-redirecting therapies: a Canadian consensus statement.T细胞重定向疗法有效使用的建议：一份加拿大共识声明。
Front Oncol. 2024 Nov 26;14:1446995. doi: 10.3389/fonc.2024.1446995. eCollection 2024.
7
Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies.在接受≥2线既往治疗后的复发或难治性滤泡性淋巴瘤患者中，对mosunetuzumab进行为期3年的长期随访。
Blood. 2025 Feb 13;145(7):708-719. doi: 10.1182/blood.2024025454.
8
Immunomodulatory Therapy for Ischemic Heart Disease.免疫调节疗法治疗缺血性心脏病。
Circulation. 2024 Sep 24;150(13):1050-1058. doi: 10.1161/CIRCULATIONAHA.124.070368. Epub 2024 Sep 23.
9
The present and future of bispecific antibodies for cancer therapy.双特异性抗体在癌症治疗中的现在和未来。
Nat Rev Drug Discov. 2024 Apr;23(4):301-319. doi: 10.1038/s41573-024-00896-6. Epub 2024 Mar 6.
10
Bispecific antibodies in indolent B-cell lymphomas.惰性B细胞淋巴瘤中的双特异性抗体
Front Immunol. 2024 Jan 11;14:1295599. doi: 10.3389/fimmu.2023.1295599. eCollection 2023.
本文引用的文献
1
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.戈利木单抗治疗复发/难治性弥漫性大 B 细胞淋巴瘤。
N Engl J Med. 2022 Dec 15;387(24):2220-2231. doi: 10.1056/NEJMoa2206913. Epub 2022 Dec 11.
2
A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma.Tisagenlecleucel 和 axicabtagene ciloleucel CAR T 细胞治疗复发或难治性弥漫性大 B 细胞淋巴瘤的真实世界比较。
Nat Med. 2022 Oct;28(10):2145-2154. doi: 10.1038/s41591-022-01969-y. Epub 2022 Sep 22.
3
Role of Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the CART Era.双特异性抗体在 CAR-T 时代复发/难治性弥漫性大 B 细胞淋巴瘤中的作用。
Front Immunol. 2022 Jul 19;13:909008. doi: 10.3389/fimmu.2022.909008. eCollection 2022.
4
Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas.商业用 axicabtagene ciloleucel 和 tisagenlecleucel 治疗复发/难治性侵袭性 B 细胞淋巴瘤患者的使用模式、结局和资源利用。
Transplant Cell Ther. 2022 Oct;28(10):669-676. doi: 10.1016/j.jtct.2022.07.011. Epub 2022 Jul 16.
5
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.在复发或难治性滤泡淋巴瘤患者中，双特异性抗体 mosunetuzumab 的安全性和疗效：一项单臂、多中心、2 期研究。
Lancet Oncol. 2022 Aug;23(8):1055-1065. doi: 10.1016/S1470-2045(22)00335-7. Epub 2022 Jul 5.
6
Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma.阿基仑赛与 tisagenlecleucel 治疗侵袭性 B 细胞淋巴瘤的比较。
Haematologica. 2023 Jan 1;108(1):110-121. doi: 10.3324/haematol.2022.280805.
7
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.西达基奥仑赛对比挽救化疗后自体干细胞移植作为二线治疗复发或难治性大 B 细胞淋巴瘤患者的标准治疗（TRANSFORM）：一项开放标签、随机、3 期临床试验的中期分析结果。
Lancet. 2022 Jun 18;399(10343):2294-2308. doi: 10.1016/S0140-6736(22)00662-6.
8
A national service for delivering CD19 CAR-Tin large B-cell lymphoma - The UK real-world experience.用于递送 CD19 CAR-T 细胞治疗大 B 细胞淋巴瘤的国家服务 - 英国真实世界经验。
Br J Haematol. 2022 Aug;198(3):492-502. doi: 10.1111/bjh.18209. Epub 2022 Apr 29.
9
Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial.奥德罗内昔单抗，一种针对 CD20 阳性 B 细胞恶性肿瘤的人源 CD20×CD3 双特异性抗体（ELM-1）：在一项单臂、多中心、1 期临床试验中，复发或难治性非霍奇金淋巴瘤队列的结果。
Lancet Haematol. 2022 May;9(5):e327-e339. doi: 10.1016/S2352-3026(22)00072-2. Epub 2022 Apr 1.
10
GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany.德国 GLA/DRST 真实世界研究分析嵌合抗原受体 T 细胞疗法治疗大 B 细胞淋巴瘤的结果。
Blood. 2022 Jul 28;140(4):349-358. doi: 10.1182/blood.2021015209.
Zotero 插件